On a different topic, I was trying to put myself i
Post# of 148187
Then I came to the one -- potentially very significant unknown. What will our label be?
If it is MDR3, then that dramatically limits our market for COMBO.
If it is MDR2 + limited treatment options in another class, then our market is substantially larger.
That would be one item I would like ironed-out prior to signing up to a deal. However, the challenge is that is likely to come very late in the game, when nearing approval. At least that is my assumption. Anyone know for sure?
+++++
The only other thing I would be negotiating hard for would be first right of refusal on MONO. Or an outright option on MONO. Why butter the bread to let another company eat it?
+++++
Or it could just be the lawyers dickering over the indemnity clause
+++++
Just some thoughts.